These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22374904)
1. Utility of GLP-1R agonists in diabetes requires long term study. de Oliveira JM BMJ; 2012 Feb; 344():e1451; author reply e1459. PubMed ID: 22374904 [No Abstract] [Full Text] [Related]
2. GLP-1R agonists are not a quick fix for weight loss. Iverson KA BMJ; 2012 Feb; 344():e1455; author reply e1459. PubMed ID: 22374905 [No Abstract] [Full Text] [Related]
8. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Morales J Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467 [TBL] [Abstract][Full Text] [Related]
9. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials. Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423 [TBL] [Abstract][Full Text] [Related]
10. GLP-1 receptor agonists today. Marre M; Penfornis A Diabetes Res Clin Pract; 2011 Sep; 93(3):317-27. PubMed ID: 21767888 [TBL] [Abstract][Full Text] [Related]
16. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists? Peterson G Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845 [TBL] [Abstract][Full Text] [Related]
17. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Hansen KB; Knop FK; Holst JJ; Vilsbøll T Int J Clin Pract; 2009 Aug; 63(8):1154-60. PubMed ID: 19624785 [TBL] [Abstract][Full Text] [Related]
18. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Drucker DJ; Nauck MA Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089 [TBL] [Abstract][Full Text] [Related]
19. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Seufert J; Gallwitz B Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150 [TBL] [Abstract][Full Text] [Related]
20. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists]. Mannucci E G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420 [No Abstract] [Full Text] [Related] [Next] [New Search]